Azerbaijani
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Ascorbic Acid Treatment in CMT1A Trial (AATIC)

Yalnız qeydiyyatdan keçmiş istifadəçilər məqalələri tərcümə edə bilərlər
Giriş / Qeydiyyatdan keçin
Bağlantı panoya saxlanılır
StatusTamamlandı
Sponsorlar
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Açar sözlər

Mücərrəd

Charcot-Marie-Tooth type IA (CMT1A) is the most prevalent hereditary peripheral neuropathy. Demyelination of peripheral nerves is the hallmark of CMT1A. Ascorbic acid has been shown to have a favorable influence on myelination in in vitro studies and in a mouse model for CMT1A. We will study the efficacy and safety of ascorbic acid treatment in young patients with CMT1A.

Təsvir

Charcot-Marie-Tooth type 1A (CMT1A), or hereditary motor and sensory neuropathy type Ia (HMSN Ia), is an autosomal dominant disease, most often caused by a 1.5 Mb duplication of chromosome 17, giving rise to three copies of the peripheral myelin protein 22 gene (PMP22). Mutations in this gene rarely cause CMT1A. It is a primarily demyelinating neuropathy, as has been shown in nerve conduction studies and in histopathological investigations. The conduction velocities of peripheral nerves are already slowed at the age of five years. Longitudinal data show that these conduction velocities do not change during life, indicating that the degree of demyelination is rather constant during life.

CMT1A is characterized clinically by distal muscle weakness and wasting, legs more than arms, impaired distal sensation, and reduced or absent reflexes. Moreover, foot and hand deformities are often encountered. In childhood, disease progression has been shown. In adults, there are indications for disease progression, but properly conducted longitudinal studies are awaited. Cross-sectional studies show that disease severity in adults is variable: a group of CMT1A patients is asymptomatic (5-10%), whereas other patients are wheelchair dependent (5-10%), still most have the classical CMT phenotype. Therapy is symptomatic and aims at maintaining functional possibilities and learning compensation mechanisms. There is no medication available that stabilizes or improves the clinical signs and symptoms.

Ascorbic acid is needed in in vitro studies for proper myelination of axons (in cultures containing serum). Recently, in a mouse model for CMT1A it has been shown that ascorbic acid improves the CMT1A phenotype. Mice (2-4 months old) treated with ascorbic acid once a week during three months showed an increase in the percentage of myelinating nerve fibers and showed better results in locomotor tests.

In this phase 2 study we will study the efficacy and safety of ascorbic acid in young patients with CMT1A. We will investigate whether ascorbic acid induces remyelination by measuring the nerve conduction of a peripheral nerve during a one year study period. CMT1A patients aged 12 years or older may cooperate sufficiently in nerve conduction studies. We include young patients, as clinical signs and symptoms especially develop relatively early in life. These signs and symptoms are due to axonal dysfunction, secondary to the demyelination. This is why we will investigate additionally whether there is an effect of ascorbic acid treatment on axonal function, strength and disabilities.

Tarixlər

Son Doğrulandı: 06/30/2008
İlk təqdim: 01/02/2006
Təxmini qeydiyyat təqdim edildi: 01/02/2006
İlk Göndərmə: 01/03/2006
Son Yeniləmə Göndərildi: 07/01/2008
Son Yeniləmə Göndərildi: 07/03/2008
Həqiqi Təhsilin Başlama Tarixi: 12/31/2005
Təxmini İlkin Tamamlanma Tarixi: 06/30/2007
Təxmini İşin Tamamlanma Tarixi: 06/30/2007

Vəziyyət və ya xəstəlik

Charcot-Marie-Tooth Disease
Hereditary Motor and Sensory Neuropathies

Müdaxilə / müalicə

Drug: 2

Drug: 1

Faza

Faza 2

Qol Qrupları

QolMüdaxilə / müalicə
Experimental: 1
Ascorbic acid
Drug: 1
Ascorbic acid 1000 mg (4 capsules of 250 mg) b.i.d. during 1 year
Placebo Comparator: 2
Placebo
Drug: 2
Placebo 4 capsules b.i.d. during 1 year

Uyğunluq Kriteriyaları

Təhsil üçün uyğun yaşlar 12 Years Üçün 12 Years
Təhsilə Uyğun CinslərAll
Sağlam Könüllüləri qəbul edirBəli
Kriteriyalar

Inclusion Criteria:

- DNA-proven CMT1A patients

- Age 12-25 years

- CMT 1A patients with symptomatology defined as muscle weakness in at least foot dorsiflexion

Exclusion Criteria:

Due to possible influence on severity of the neuropathy:

- Known other disease that may cause a neuropathy, that may decrease mobility, or that may lead to severe disability or death in a short time

- Medication that may cause a neuropathy

- Chronic alcohol abuse

Due to study medication (ascorbic acid):

- Regular use of vitamin C

- Clinical or echographic signs of nephrolithiasis

- Reduced glomerular filtration rate

- Iron overload

- No regular dental control at the dentist

- Pregnancy or active pregnancy wish for women

Due to study design and primary outcome:

- Not signing the informed consent

- Psychiatric co-morbidity which may influence compliance

- Not being comfortable during nerve conduction studies of the median nerve

- A too small CMAP amplitude of the abductor pollicis brevis muscle for a proper determination of the nerve conduction velocity of the median nerve

Nəticə

İlkin nəticə tədbirləri

1. Change in motor nerve conduction velocity of the median nerve after 1 year [1 year]

İkincili Nəticə Tədbirləri

1. Change in minimal F response latency of the median nerve after 1 year [1 year]

2. Changes in compound muscle action potential amplitude and area after 1 year [1 year]

3. Change in motor unit number estimation of the abductor pollicis brevis muscle after 1 year [1 year]

4. Changes in handgrip strength, strength of armflexors, foot dorsiflexors, knee extensors and hip flexors after 1 year [1 year]

5. Change in overall disability sum score after 1 year [1 year]

6. Change in AMC Linear Disability Scale score after 1 year [1 year]

7. Evaluation of serum ascorbic acid concentrations during 1 year [1 year]

8. Evaluation of side effects during 1 year [1 year]

Facebook səhifəmizə qoşulun

Elm tərəfindən dəstəklənən ən tam dərman bitkiləri bazası

  • 55 dildə işləyir
  • Elm tərəfindən dəstəklənən bitki mənşəli müalicələr
  • Təsvirə görə otların tanınması
  • İnteraktiv GPS xəritəsi - yerdəki otları etiketləyin (tezliklə)
  • Axtarışınızla əlaqəli elmi nəşrləri oxuyun
  • Təsirlərinə görə dərman bitkilərini axtarın
  • Maraqlarınızı təşkil edin və xəbər araşdırmaları, klinik sınaqlar və patentlər barədə məlumatlı olun

Bir simptom və ya bir xəstəlik yazın və kömək edə biləcək otlar haqqında oxuyun, bir ot yazın və istifadə olunan xəstəliklərə və simptomlara baxın.
* Bütün məlumatlar dərc olunmuş elmi araşdırmalara əsaslanır

Google Play badgeApp Store badge